AstraZeneca PLC

Explore how AstraZeneca’s Q4 2025 earnings reveal a sharp rise in profit driven by oncology sales, a £3.5 bn pipeline push, and a 12 % dividend hike, setting a cautious 2026 outlook amid patent and regulatory challenges.

Explore how AstraZeneca’s earnings, R&D pipeline, and market‑access strategies shape its valuation and future growth potential.

Explore why AstraZeneca’s future is both bullish and cautious after its Nasdaq‑100 exit, and how index rebalancing, pharma fundamentals, and macro trends shape investor outlook.

Stable AstraZeneca PLC shares, a diversified therapeutic pipeline, and proactive regulatory strategy signal continued confidence and growth prospects for investors.

Read how AstraZeneca’s latest update shows a mix of oncology setbacks, a breakthrough therapy win for Enhertu, and a strategic exit from Andexxa, illustrating the company’s dynamic portfolio strategy and regulatory moves.

Read how AstraZeneca’s oncology mix—lung‑cancer setback vs. breast‑cancer breakthrough and safety‑driven product pull—shows its strategic resilience.

Discover why AstraZeneca’s ovarian‑cancer phase‑three study and strategic market‑access plan could boost its $26 billion revenue forecast and 12 % IRR—read the latest analyst insights and M&A prospects.

Imfinzi’s FDA approval for peri‑operative gastric cancer marks a breakthrough, pairing powerful immunotherapy with FLOT chemotherapy to cut progression risk by 28% and boosting AstraZeneca’s market and patient‑care impact.

Explore AstraZeneca’s NYSE direct listing and 2025 earnings forecast—EPS up 5.5%, liquidity strengths, and risks of patent expirations.

Read how AstraZeneca’s shareholder‑approved NYSE direct listing will boost capital for oncology and cardiovascular R&D, improve market visibility, and speed patient access to new therapies.